Additionally, the 36-month beta value for IRON is 0.73. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IRON is 21.08M and currently, short sellers hold a 14.69% ratio of that float. The average trading volume of IRON on June 19, 2025 was 443.27K shares.
IRON) stock’s latest price update
Disc Medicine Inc (NASDAQ: IRON)’s stock price has gone rise by 0.08 in comparison to its previous close of 50.05, however, the company has experienced a -1.51% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-06-12 that WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 5 posters presented at the EHA 2025 annual meeting in Milan, Italy. This year’s presentations included data from HELIOS, an ongoing open-label extension study of bitopertin in EPP, which showed favorable long-term efficacy and safety with sustained protoporphyrin IX (PPIX) reductions, improvement in quality of life, and improved liver biomarkers. Disc is advancing development and registrational activities for bitopertin in EPP, with plans to submit an NDA in H2 2025. The company has initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP. Disc recently launched a campaign to raise awareness of EPP among physicians, patients, and caregivers with emphasis on the causative role of PPIX accumulation in the disease. Learn more at PPIXisWhy.com.
IRON’s Market Performance
Disc Medicine Inc (IRON) has seen a -1.51% fall in stock performance for the week, with a 0.82% gain in the past month and a -6.79% plunge in the past quarter. The volatility ratio for the week is 2.72%, and the volatility levels for the past 30 days are at 2.71% for IRON. The simple moving average for the last 20 days is 1.89% for IRON’s stock, with a simple moving average of -5.50% for the last 200 days.
Analysts’ Opinion of IRON
Many brokerage firms have already submitted their reports for IRON stocks, with Raymond James repeating the rating for IRON by listing it as a “Strong Buy.” The predicted price for IRON in the upcoming period, according to Raymond James is $89 based on the research report published on June 11, 2025 of the current year 2025.
Morgan Stanley gave a rating of “Overweight” to IRON, setting the target price at $85 in the report published on November 05th of the previous year.
IRON Trading at 8.11% from the 50-Day Moving Average
After a stumble in the market that brought IRON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.12% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRON starting from Franchi Jean M., who sale 2,000 shares at the price of $52.26 back on Jun 16 ’25. After this action, Franchi Jean M. now owns 67,530 shares of Disc Medicine Inc, valued at $104,519 using the latest closing price.
JEAN FRANCHI, the Officer of Disc Medicine Inc, proposed sale 2,000 shares at $53.71 during a trade that took place back on Jun 16 ’25, which means that JEAN FRANCHI is holding shares at $107,420 based on the most recent closing price.
Stock Fundamentals for IRON
The total capital return value is set at -0.2. Equity return is now at value -23.34, with -21.91 for asset returns.
Based on Disc Medicine Inc (IRON), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -3.32. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -94.08.
Currently, EBITDA for the company is -108.27 million with net debt to EBITDA at 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 37.65.
Conclusion
In conclusion, Disc Medicine Inc (IRON) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
